Cure Rare Disease Secures CIRM Grant to Advance SCA3 Therapy
Cure Rare Disease Receives Significant Funding for Gene Therapy
Cure Rare Disease (CRD) has announced it has been granted a substantial $5.69 million from the California Institute for Regenerative Medicine (CIRM). This funding marks a pivotal advancement in their effort to develop an innovative antisense oligonucleotide therapy aimed at treating spinocerebellar ataxia type 3 (SCA3), a serious neurodegenerative disorder that currently lacks effective treatment options.
Background on the Development of SCA3 Therapy
The journey of Cure Rare Disease’s SCA3 program began in 2021, initiated with the aspiration to create a targeted antisense oligonucleotide (ASO) therapy. One of the key motivators behind this program was Gregory Klassen, a patient grappling with the challenges of SCA3, who provided early funding support, illustrating the vital role that patient contributions play in advancing rare disease research.
Between 2022 and 2023, researchers at Cure Rare Disease, in collaboration with Leiden University Medical Center, carried out a series of studies using a mouse model of SCA3. These studies have yielded promising results, indicating functional improvements that lend hope to the development of effective therapies for those affected by this condition.
Regulatory Milestones and Clinical Trials Ahead
An important milestone occurred in 2024 when the team held a Type B pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA). This meeting provided crucial regulatory guidance for the design of future clinical trials and for the scale-up of necessary manufacturing processes.
The CIRM funding will facilitate the completion of these manufacturing processes, enabling the conduct of IND-enabling toxicology studies. Following these studies, the team plans to submit an IND application to kickstart early-stage clinical trials. The leadership of Dr. Susan Perlman at UCLA will spearhead these groundbreaking trials, aiming to bring this innovative therapy closer to reality.
A Collaborative Effort for Rare Disease Treatment
In expressing his gratitude for the significant CIRM support, Richard Horgan, CEO and founder of Cure Rare Disease, remarked on the collaborative nature of the project. He emphasized that the combined efforts of patients, researchers, regulatory bodies, and healthcare industry partners have created a powerful framework for the development of new therapies. Horgan stated, "We are incredibly appreciative of CIRM’s support in helping us take this program into the clinic, proving that rare disease treatments can be brought to patients through our model of collective dedication and innovation."
Understanding Spinocerebellar Ataxia Type 3
Spinocerebellar ataxia type 3 (SCA3) is recognized as the most prevalent variant of spinocerebellar ataxia, affecting an estimated one to five individuals per 100,000. This condition stems from mutations in the ATXN3 gene, which is responsible for producing the protein ataxin-3. This protein plays a critical role in managing damaged proteins within the body, and mutations lead to a dangerous accumulation of toxic components, drastically affecting motor function and stability.
About Cure Rare Disease (CRD)
Cure Rare Disease is a nonprofit biotechnology entity dedicated to advancing genetic medicine for rare and ultra-rare diseases. Through a patient-centric approach, CRD is fervently committed to accelerating the development of effective treatments tailored for individuals afflicted by these rare conditions. Among its various initiatives, CRD focuses on gene therapy and antisense oligonucleotide (ASO) treatments, driving progress toward a brighter future for patients in need.
About the California Institute for Regenerative Medicine (CIRM)
The California Institute for Regenerative Medicine operates as a funding agency with the noble mission of fast-tracking regenerative medicine research to deliver meaningful treatment options for conditions with significant unmet medical needs. Originating in 2004 through Proposition 71, CIRM has been instrumental in funding extensive research endeavors in stem cell and genetic science, fostering innovations that aim to benefit diverse communities across California.
Frequently Asked Questions
What is the purpose of the grant awarded to Cure Rare Disease?
The grant from CIRM aims to support the development of a gene therapy for SCA3, enabling manufacturing scale-up and clinical trial preparations.
When did Cure Rare Disease start its SCA3 program?
The SCA3 program was launched in 2021, focusing on developing an effective ASO therapy for the condition.
Who is leading the upcoming clinical trials?
Dr. Susan Perlman will lead the clinical trials at UCLA as part of the SCA3 therapy development effort.
What is the significance of the FDA's Type B pre-IND meeting?
This meeting provided essential regulatory guidance that will aid in the design of clinical trials and the manufacturing process for the gene therapy.
What is the broader vision of Cure Rare Disease?
Cure Rare Disease aims to accelerate the development of genetic medicines for rare diseases, prioritizing a patient-centric approach in all its research initiatives.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
